Organon & Co | OGN - Capital Social Ordinario





Capital Social Ordinario Cambio Fecha
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Celltrion KRW 229.65M 11.03M 2026-03
Cspc Pharmaceutical CNY 11.52B 3.7M 2025-12
Deva Holding AS TRY 200.02M 0 2023-09
Dianthus Therapeutics USD 54.58M 11.36M 2026-03
Divis Laboratories Ltd INR 265.47M 0 2026-03
Gilead Sciences USD 1.24B 1000K 2026-06
Glaxosmithkline GBP 4.05B 20.6M 2026-03
Kangmei Pharma CNY 13.83B 0 2026-03
Knight Therapeutics CAD 99.68M 24.66K 2025-09
Laboratorios Farma EUR 51.82M 1.55M 2023-12
Malin Corporation EUR 200K 0 2024-12
Medical Developments International AUD 112.66M 2.35M 2025-12
Merck USD 2.47B 4.93M 2026-03
Neuren Pharmaceuticals AUD 126.64M 38.63M 2025-12
Novartis USD 1.91B 60K 2026-03
Organigram Holdings CAD 136.47M 1.34M 2026-03
Organon & Co USD 262.61M 40K 2026-06
Ovoca Bio EUR 29.49M 0 2025-12
Pharma Mar EUR 17.34M 24.24K 2026-06
Qiagen NV USD 206.5M 245K 2026-06
Sartorius EUR 69.05M 0 2026-06
Sino Biopharmaceutical CNY 17.89B 30.5M 2025-06
Tilray USD 116.52M 5.01M 2025-09
Zealand Pharma A/S 70.66M 53K 2026-03